Study finds high costs, few benefits associated with GLP-1 weight loss drugs
A new study from a pharmacy benefit manager is casting doubt on the benefits of GLP-1 drugs used for weight loss, finding they are associated with a high cost of care with little benefit beyond dropping pounds.
The Diet Industry Is Reportedly in Total Meltdown Over GLP-1 Weight Loss Drugs
With weight loss injectables like Ozempic and Mounjaro taking the world by storm, the diet industry is seemingly being left in the dust.
How Ozempic, GLP-1 Weight Loss Drugs Affect the Brain to Curb Substance Misuse
A recent study found significant reductions in opioid overdose and alcohol misuse among people taking GLP-1 drugs like Ozempic.
GLP-1 Stocks Aren't the Only Way to Benefit From the Weight Loss Drugs Boom
The future of the weight loss market might not revolve around GLP-1 drugs.
Study: GLP-1 weight-loss drugs might lower, not increase, teen suicide risk
In a new study, obese kids who used GLP-1 weight-loss drugs had a 33% decline in their risk for thoughts of suicide and suicide attempts compared to adolescents who didn't.
US Medicaid Programs Say Cost a Key Factor for Weight-Loss Drug Coverage, Survey Finds
The survey of the 50 states and the District of Columbia found that just 12 Medicaid programs covered the drugs to treat obesity as of July 2024 with some limits on use. Half of the states without coverage said they are considering adding them or evaluating their coverage,
More state Medicaid programs consider covering GLP-1 drugs
While all state Medicaid programs cover GLP-1 agonists for type 2 diabetes, it’s much less common for them to cover the drugs for obesity. Currently, just 13 state Medicaid programs cover GLP-1s for obesity.
Do 'Natural GLP-1 Supplements' Actually Work? Here's What Experts Think.
Food naturally boosts your body’s GLP-1 levels, explained Dr. Sun Kim, an endocrinologist at Stanford Health Care in ...
Medpage Today on MSN17h
GLP-1 Drugs Tied to Reduced Risk of Uterine Fibroids
Among patients who took at least two doses of medication, GLP-1 receptor agonists were associated with a significantly lower ...
BioSpace1d
GLP-1 Prescriptions for Type 1 Diabetes Spike Despite Lack of FDA Approval: Study
While the regulator has not approved their use in type 1 diabetes, off-label prescribing for GLP-1 receptor agonists has ...
HR Dive21h
Employees are asking about GLP-1 coverage. What should employers do?
For GLP-1 treatment in particular, employers “need to make sure the coverage is married with a patient engagement program, ...
Medpage Today on MSN2d
No X-Ray Proof of Rare Surgical Complication Tied to GLP-1 Agonists
However, the number of verified aspiration events came out to just 20 events, all identified from anesthesia notes and all in ...
Medscape1d
Rise in GLP-1 RA and SGLT2 Inhibitor Prescribing in Patients With T1D
An analysis of over 400,000 patients with T1D revealed a rise in prescribing for glucagon-like peptide 1 receptor agonists and sodium-glucose cotransporter 2 inhibitors over the past decade.
Ozempic may significantly lower the risk of Alzheimer’s disease — here’s how
Nearly 7 million Americans 65 and older are living with Alzheimer’s disease, which gradually destroys memory and thinking ...
TCTMD2d
Defying Earlier GLP-1 Data, Study in Teens Sees Possible Mental Health Gains
The retrospective study points to fewer suicidal thoughts or attempts among adolescents taking semaglutide or liraglutide.